FROM Hem/Onc today
*recent study suggests that the survival is not affected by Breast cancer diagnosed during pregnancy.
*IMRT offers lesser local adverse effects than standard RT in patients with early breast cancer
*Maintenance therapy with Gemzar-Taxol  improves Progression free and overall survival in patient with metastatic breast cancer (32.3 Vs 25.5 months)

*A study at Baylor suggested circulating tumor DNA to be an "effective Biomarker in Breast cancer".
*Bendamustine and Rituxan appears to be an effective regimen in relapse Diffuse large B-cell lymphoma  with ORR 67% and CR 37%, patients received a large dose of Bendamustine (120mg/m2) on day2,3 with  great frequency of marrow toxicity.

*21 day R-CHOP (instead of 2weeks) remains the recommended standard in Lymphoma.
*As expected, Tivozanib received a thumb down by the FDA for Renal Cell Cancer,  and DARATUMUMAB (Anti-CD 38) RECEIVED "the one to watch status" or Breakthrough status in Myeloma.  FDA also approved  Tafinlar,Mekinist for Melanoma.
*There is such thing as "an inappropriate Colonoscopy" by age of patients!
*OF SIGNIFICANCE, ZIBOTENTAN/TAXOTERE FAILED TO IMPROVE  OVERALL SURVIVAL IN PATIENT WITH HORMONE REFRACTORY PROSTATE CANCER,  AND REMEMBER A CANADIAN STUDY SUGGESTED THAT CETUXIMAB FAILED TO DO THE SAME DESPITE AN INCREASING RATE OF EGFR IN ADVANCING HRPC
*Once again Duloxetine works in Chemotherapy induced peripheral Neuropathy...
*don't run out of name,and not making it up!, Nintedamib good for Renal cell cancer, as good as Sunitinib,they say!
=======================================================
CAN PATIENT WITH WITH E.COLI POSITIVE TEST SHOW AN AMPLIFIED NF-kB AND HIGHER LEVEL OF CYCLINS (INTERFERON OR INTERLEUKINES) IN THEIR PERIPHERAL BLOOD CELLS AND SERUM (PICK THE RIGHT MEDIA FOR YOUR TESTING)?
================================================================